Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Lynne A Bui"'
Autor:
Matthias Hundt, Ivan Hernandez, Pratima Kundu, Sahil Inamdar, Carlos A Obejero-Paz, Nigel G Kooreman, Stephen D Wolpe, Lynne A Bui, Skylar R Foust
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/91ca99052f2a4a958b4288a71e526483
Autor:
Hui Huang, Matthias Hundt, Ivan Hernandez, Pratima Kundu, Sahil Inamdar, Hong Dai, Carlos A Obejero-Paz, Nigel G Kooreman, Stephen D Wolpe, Lynne A Bui
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f2b4d80889f04684878023e2fc3eae34
Autor:
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss, on behalf of the ABOUND.70+ Investigators, Ajeet Gajra, Andrei Dobrescu, Bohdan E. Halibey, Corey Langer, Daniel Haggstrom, Eric Anderson, Eugene H. Paschold, Haiying Cheng, Haythem Ali, Hossein Borghaei, Jawad Elias Francis, Ayla Ahmed Kessler, Jen C. Wang, Jonathan Wade Goldman, Jose E. Najera, Nadim F. Nimeh, Joseph Rosales, Konstantin H. Dragnev, Leonardo Forero, Lynne A. Bui, Marc R. Matrana, Maurice Willis, Monika Joshi, Morton Coleman, Moses Sundar Raj, Navkiranjit Gill, Patricia M. Plezia, Manuel R. Modiano, R. Timothy Webb, Rita Axelrod, Robert Andrew Dichmann, Ronald P. Harris, Scott Anthony Sonnier, Vijay Patel, Shaker R. Dakhil, Tarek Mekhail, Thomas Hensing, Tony M. Samaha, Vicky Lee, Kimberly McGregor, William Eyre Lawler, William L. Skinner, William T. DeRosa
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally adv
Externí odkaz:
https://doaj.org/article/6b1a3f05e7d740d8aebb050cd6890afd
Autor:
Mojun Zhu, Laura W. Goff, Mudgal Kothekar, Grace K. Dy, George A. Fisher, Antonio Jimeno, Elaine T. Lam, Jennifer R. Diamond, Lynne A. Bui, S. Gail Eckhardt, Alex A. Adjei, Akhil Sanghal, Geetanjali Chimote, Wen Wee Ma, Steven R. Alberts, Ajay Khopade, Robert Faulkner
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:779-788
Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study examined the safety, tolerability, pharmacokinetics and maximum tolerated dose (MTD) of PICN alone and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca90b20ba6a4590953e4acd9a8ef881
https://doi.org/10.1007/s00280-021-04235-z
https://doi.org/10.1007/s00280-021-04235-z
Autor:
Wen Wee, Ma, Mojun, Zhu, Elaine T, Lam, Jennifer R, Diamond, Grace K, Dy, George A, Fisher, Laura Williams, Goff, Steven, Alberts, Lynne A, Bui, Akhil, Sanghal, Mudgal, Kothekar, Ajay, Khopade, Geetanjali, Chimote, Robert, Faulkner, S Gail, Eckhardt, Alex A, Adjei, Antonio, Jimeno
Publikováno v:
Cancer chemotherapy and pharmacology. 87(6)
Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study examined the safety, tolerability, pharmacokinetics and maximum tolerated dose (MTD) of PICN alone and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f37c0ff84c83020f6b54c70b698d5c2b
https://pubmed.ncbi.nlm.nih.gov/33634324
https://pubmed.ncbi.nlm.nih.gov/33634324
Autor:
Patrycja Olszynski, Douglas O. Clary, Lynne A. Bui, Hagop M. Kantarjian, Jorge E. Cortes, Neil P. Shah, Srdan Verstovsek, Constantine S. Tam, Catherine C. Smith, Martha Wadleigh, Chunyan Song, Lubomir Sokol
Publikováno v:
Leukemia research, vol 38, iss 3
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290179151b1300506217f235a57b4897
https://doi.org/10.1016/j.leukres.2013.12.006
https://doi.org/10.1016/j.leukres.2013.12.006
Autor:
Carrie T. Taylor, Lynne A. Bui
Publikováno v:
Seminars in Oncology. 41:S15-S25
Biosimilars offer the prospect of providing efficacious and safe treatment options for many diseases, including cancer, while potentially increasing accessibility with greater affordability relative to biologics. Because biologics are large, complex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af0d6d38af4f8f3fe50452c70754135
https://doi.org/10.1053/j.seminoncol.2013.12.002
https://doi.org/10.1053/j.seminoncol.2013.12.002
Autor:
Beverly Ingram, Chee-Keng Ng, Lynne A. Bui, Ira Jacobs, Anne M. Ryan, Carol F. Kirchhoff, Susan Hurst, Gregory L. Finch
Publikováno v:
Drug discovery today. 20
Biosimilar development requires several steps: selection of an appropriate reference biologic, understanding the key molecular attributes of that reference biologic and development of a manufacturing process to match these attributes of the reference
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b1286b76b8a3efbffeb76c81259ce18
https://pubmed.ncbi.nlm.nih.gov/25912284
https://pubmed.ncbi.nlm.nih.gov/25912284
Autor:
Lynne A. Bui
Publikováno v:
Drug Discovery Today. 20:1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7f585b095b7462097b53febdf2af31
https://doi.org/10.1016/j.drudis.2015.03.016
https://doi.org/10.1016/j.drudis.2015.03.016
Autor:
Lisa H. Butterfield, Syed M. Jilani, Nitya G. Chakraborty, Lynne A. Bui, Antoni Ribas, Vivian Beck Dissette, Roy Lau, Seth C. Gamradt, John A. Glaspy, William H. McBride, Bijay Mukherji, James S. Economou
Publikováno v:
The Journal of Immunology. 161:5607-5613
Dendritic cells (DC) are potent stimulators of primary T cell responses. In this study, we demonstrate that DC, genetically engineered to express the MART-1/Melan-A (MART-1) tumor-associated Ag, express MART-1 mRNA and protein, correctly process and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4865b9f9bb91eb795888e9717f3d436
https://doi.org/10.4049/jimmunol.161.10.5607
https://doi.org/10.4049/jimmunol.161.10.5607